5 results on '"Loukas, Alex"'
Search Results
2. The yin and yang of human soil-transmitted helminth infections.
- Author
-
Loukas A, Maizels RM, and Hotez PJ
- Subjects
- Ancylostomatoidea, Animals, Humans, Prevalence, Soil parasitology, Trichuris, Ascariasis, Helminthiasis drug therapy, Helminthiasis prevention & control, Helminths, Hookworm Infections drug therapy, Hookworm Infections prevention & control, Nematoda, Trichuriasis, Vaccines
- Abstract
The major soil-transmitted helminths that infect humans are the roundworms, whipworms and hookworms. Soil-transmitted helminth infections rank among the most important neglected tropical diseases in terms of morbidity, and almost one billion people are still infected with at least one species. While anthelmintic drugs are available, they do not offer long term protection against reinfection, precipitating the need for vaccines that provide long-term immunologic defense. Vaccine discovery and development is in advanced clinical development for hookworm infection, with a bivalent human hookworm vaccine in clinical trials in Brazil and Africa, but is in its infancy for both roundworm (ascariasis) and whipworm (trichuriasis) infections. One of the greatest hurdles to developing soil-transmitted helminth vaccines is the potent immunoregulatory properties of these helminths, creating a barrier to the induction of meaningful long-term protective immunity. While challenging for vaccinologists, this phenomenon presents unique opportunities to develop an entirely new class of anti-inflammatory drugs that capitalise on these immunomodulatory strategies. Epidemiologic studies and clinical trials employing experimental soil-transmitted helminth challenge models, when coupled with findings from animal models, show that at least some soil-transmitted helminth-derived molecules can protect against the onset of autoimmune, allergic and metabolic disorders, and several natural products with the desired bioactivity have been isolated and tested in pre-clinical settings. The yin and yang of soil-transmitted helminth infections reflect both the urgency for effective vaccines and the potential for new immunoregulatory molecules from parasite products., (Copyright © 2021 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
3. Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression.
- Author
-
Dalton JP, Brindley PJ, Knox DP, Brady CP, Hotez PJ, Donnelly S, O'Neill SM, Mulcahy G, and Loukas A
- Subjects
- Animals, DNA, Circular analysis, Endopeptidases genetics, Escherichia coli genetics, Fermentation genetics, Gene Expression genetics, Genome, Helminthiasis genetics, Helminthiasis, Animal genetics, Helminthiasis, Animal prevention & control, Helminths genetics, Humans, Insecta genetics, Recombinant Proteins genetics, Yeasts genetics, Genes, Helminth genetics, Helminthiasis prevention & control, Vaccines therapeutic use
- Abstract
The control of helminth diseases of people and livestock continues to rely on the widespread use of anti-helminthic drugs. However, concerns with the appearance of drug resistant parasites and the presence of pesticide residues in food and the environment, has given further incentive to the goal of discovering molecular vaccines against these pathogens. The exponential rate at which gene and protein sequence information is accruing for many helminth parasites requires new methods for the assimilation and analysis of the data and for the identification of molecules capable of inducing immunological protection. Some promising vaccine candidates have been discovered, in particular cathepsin L proteases from Fasciola hepatica, aminopeptidases from Haemonchus contortus, and aspartic proteases from schistosomes and hookworms, all of which are secreted into the host tissues or into the parasite intestine where they play important roles in host-parasite interactions. Since secreted proteins, in general, are exposed to the immune system of the host they represent obvious candidates at which vaccines could be targeted. Therefore, in this article, we consider the potential values and uses of algorithms for characterising cDNAs amongst the collated helminth genomic information that encode secreted proteins, and methods for their selective isolation and cloning. We also review the variety of prokaryotic and eukaryotic cell expression systems that have been employed for the production and downstream purification of recombinant proteins in functionally active form, and provide an overview of the parameters that must be considered if these recombinant proteins are to be commercialised as vaccine therapeutics in humans and/or animals.
- Published
- 2003
- Full Text
- View/download PDF
4. Schistosome membrane proteins as vaccines
- Author
-
Loukas, Alex, Tran, Mai, and Pearson, Mark S.
- Subjects
- *
SCHISTOSOMA , *VACCINES , *MEMBRANE proteins , *IMMUNE response - Abstract
Abstract: Schistosomes are parasitic blood flukes that infect approximately 200 million people and are arguably the most important human helminth in terms of mortality. The outermost surface of intra-mammalian stages of the parasite, the tegument, is the key to the parasite’s success, but it is also generally viewed as the most susceptible target for vaccines and drugs. Over the past 2 years the proteome of the Schistosoma mansoni tegument has been investigated and these studies revealed surprisingly few proteins that are predicted to be accessible to the host immune response, namely proteins with at least one membrane-spanning domain. However, of this handful of proteins, some are showing great promise as recombinant vaccines against schistosomiasis at a pre-clinical level. In particular, the tetraspanin family of integral membrane proteins appears to be abundantly represented in the tegument, and convergent data using the mouse vaccine model and correlates of protective immunity in naturally exposed people suggests that this family of membrane proteins offer great promise for schistosomiasis vaccines. With the recent advances in schistosome genomics and proteomics, a new suite of potential vaccine antigens are presented and these warrant detailed investigation and appropriate funding over the next few years. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
5. Progress in the development of a recombinant vaccine for human hookworm disease: The Human Hookworm Vaccine Initiative
- Author
-
Hotez, Peter J., Zhan, Bin, Bethony, Jeffrey M., Loukas, Alex, Williamson, Angela, Goud, Gaddam Narsa, Hawdon, John M., Dobardzic, Azra, Dobardzic, Reshad, Ghosh, Kashinath, Bottazzi, Maria Elena, Mendez, Susana, Zook, Bernard, Wang, Yan, Liu, Sen, Essiet-Gibson, Idong, Chung-Debose, Sophia, Xiao, Shuhua, Knox, David, and Meagher, Michael
- Subjects
- *
HOOKWORMS , *PARASITES , *INFECTION , *IMMUNE response - Abstract
Hookworm infection is one of the most important parasitic infections of humans, possibly outranked only by malaria as a cause of misery and suffering. An estimated 1.2 billion people are infected with hookworm in areas of rural poverty in the tropics and subtropics. Epidemiological data collected in China, Southeast Asia and Brazil indicate that, unlike other soil-transmitted helminth infections, the highest hookworm burdens typically occur in adult populations, including the elderly. Emerging data on the host cellular immune responses of chronically infected populations suggest that hookworms induce a state of host anergy and immune hyporesponsiveness. These features account for the high rates of hookworm reinfection following treatment with anthelminthic drugs and therefore, the failure of anthelminthics to control hookworm. Despite the inability of the human host to develop naturally acquired immune responses to hookworm, there is evidence for the feasibility of developing a vaccine based on the successes of immunising laboratory animals with either attenuated larval vaccines or antigens extracted from the alimentary canal of adult blood-feeding stages. The major antigens associated with each of these larval and adult hookworm vaccines have been cloned and expressed in prokaryotic and eukaryotic systems. However, only eukaryotic expression systems (e.g., yeast, baculovirus, and insect cells) produce recombinant proteins that immunologically resemble the corresponding native antigens. A challenge for vaccinologists is to formulate selected eukaryotic antigens with appropriate adjuvants in order to elicit high antibody titres. In some cases, antigen-specific IgE responses are required to mediate protection. Another challenge will be to produce anti-hookworm vaccine antigens at high yield low cost suitable for immunising large impoverished populations living in the developing nations of the tropics. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.